UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________________________________
FORM 8-K
_______________________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 31, 2022 (January 31, 2022)
_______________________________________________
(Exact name of registrant as specified in its charter)
_______________________________________________________
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (zip code)
Registrant’s telephone number, including area code: (512 ) 314-3400
_______________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | |||||||||||||||
| (NASDAQ Global Select Market) | |||||||||||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging growth company | |||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 — Submission of Matters to a Vote of Security Holders
On January 31, 2022, the sole holder of the Company’s Class B Voting Common Stock (the “Voting Stockholder”) ratified certain “defective corporate acts” (as such term is defined in Section 204(h) of the General Corporation Law of the State of Delaware (the “DGCL”)) relating to the Company’s 2010 Long-Term Incentive Plan (the “Plan”). The ratification was approved by the Company’s Board of Directors (the “Board”) prior to submission to the Voting Stockholder.
The Plan was originally approved by the Board and the Voting Stockholder and became effective May 1, 2010. As originally approved, Section 1.2 of the Plan provided that “no Award shall be granted under the plan after the tenth anniversary of the Effective Date.” Since May 1, 2020, the Company has continued to grant awards under the Plan. The failure to amend the Plan to extend the end-date for making awards under the Plan was inadvertent and an unintentional oversight by Company personnel. All of the awards granted since May 1, 2020 have been part of the Company’s customary and ongoing long-term incentive compensation program for directors, executive officers and other key employees; have been reviewed and approved by the Company’s Executive Chairman (who is also the sole beneficial owner of the Voting Stockholder) and by the People and Compensation Committee of the Board; have been disclosed and discussed in the “Executive Compensation” section of the Company’s Annual Reports on Form 10-K; have been fully reflected in the Company’s annual and quarterly financial statements; and for directors and executive officers, have been reported on periodic Section 16 filings. A complete list of those awards is attached as a schedule to the Board resolutions approving the ratification, which are included in Exhibit 99.1 to this Current Report on Form 8-K (this “Report”).
The ratification described above was implemented pursuant to Section 204 of the DGCL. This Report, including Exhibit 99.1 (which is incorporated herein by reference), shall constitute the notice to stockholders required by Sections 204 and 228(e) of the DGCL.
Item 9.01 — Financial Statements and Exhibits
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EZCORP, INC. | |||||||||||||||||||||||
| Date: | January 31, 2022 | By: | /s/ Thomas H. Welch, Jr. | ||||||||||||||||||||
| Thomas H. Welch, Jr. | |||||||||||||||||||||||
| Chief Legal Officer and Secretary | |||||||||||||||||||||||
NOTICE OF RATIFICATION AND
ACTION BY WRITTEN CONSENT OF
THE STOCKHOLDERS OF
EZCORP, INC.
THE STOCKHOLDERS OF
EZCORP, INC.
January 31, 2022
Dear Stockholder:
NOTICE IS HEREBY GIVEN pursuant to Section 228(e) of the General Corporation Law of the State of Delaware (the “DGCL”) that, in connection with the ratification of certain “defective corporate acts” (as defined in Section 204(h) of the DGCL) identified in the Board Resolutions (as defined below) pursuant to and in accordance with Section 204 of the DGCL (collectively, the “Acts” and the ratification thereof, the “Ratification”), a written consent (the “Stockholder Consent”) of the sole holder of the outstanding shares of Class B Voting Common Stock, $0.01 par value per share (the “Class B Voting Common Stock”), of EZCORP, Inc., a Delaware corporation (the “Company”), representing the requisite vote of the stockholders of the Company to approve the ratification of each of the Acts and matters set forth therein, was executed and delivered to the Company in accordance with the DGCL on January 31, 2022. Upon the execution and delivery of the Stockholder Consent on January 31, 2022, the ratification of the Acts became effective (the “Validation Effective Time”). A copy of the resolutions of the Board of Directors of the Corporation (the “Board”) authorizing the Ratification is attached as Exhibit A to this Notice and incorporated herein by reference (the “Board Resolutions”). Pursuant to the Stockholder Consent, the holder of all of the outstanding shares of Class B Voting Common Stock also expressly approved and ratified the Plan Amendment (as defined in the Board Resolutions) and ratified the Board’s approval of the Ratification in all respects.
This Notice is being given on January 31, 2022 to the persons, other than the holder of all of the outstanding shares of Class B Voting Common Stock who executed and delivered the Stockholder Consent, who were the holders of record of the issued and outstanding shares capital stock of the Company as of the close of business on January 31, 2022, being the date that the Board Resolutions were adopted and the Stockholder Consent was delivered to the Company. This Notice is also being given to each holder of valid and putative stock entitled thereto, whether voting or nonvoting, as of January 31, 2022, and as of the date of each of the Acts, other than those persons who executed and delivered the Stockholder Consent or who otherwise consented to or waived notice of the Ratification in writing.
This Notice shall constitute the notice of stockholder action without a meeting required by Section 228(e) of the DGCL and shall also constitute any notice required under Section 204 of the DGCL. Additionally, under Section 204 of the DGCL, any claim that the any of the Acts or putative stock referenced in the Board Resolutions ratified under Section 204 of the DGCL is void or voidable due to the failure(s) of authorization set forth therein, or that the Delaware Court of Chancery should declare in its discretion that the ratification thereof in accordance with Section 204 of the DGCL not be effective or be effective only on certain conditions, must be brought within the later of 120 days from the Validation Effective Time or the time at which this Notice is given.
EZCORP, INC.
By: /s/ THOMAS H. WELCH, JR.
Thomas H. Welch, Jr.
Chief Legal Officer and Secretary
EXHIBIT A
Board Resolutions
EZCORP, INC.
UNANIMOUS WRITTEN CONSENT OF THE BOARD OF DIRECTORS
January 31, 2022
Each of the undersigned, collectively constituting all of the members of the Board of Directors of
EZCORP, Inc., a Delaware corporation (the “Company”), pursuant to Section 141(f) of the General Corporation Law of the State of Delaware (the “DGCL”), DOES HEREBY CONSENT to the adoption of, and DOES HEREBY ADOPT, the following resolutions:
WHEREAS, pursuant to the Amended and Restated EZCORP, Inc. 2010 Long-Term Incentive Plan, effective November 28, 2018 (the “Plan”), the Company is authorized to grant and issue Awards consisting of Stock Options, Stock Appreciation Rights, Stock Bonuses, Restricted Stock, Restricted Stock Units or Performance Shares (as such terms are defined in the Plan, and capitalized terms used and not defined herein have the meaning set forth in the Plan) in respect of the shares of the Company’s Class A Non-Voting Common Stock, $0.01 par value per share (the “Class A Non-Voting Common Stock”);
WHEREAS, although Section 1.2 of the Plan provided that no Award shall be granted under the Plan after May 1, 2020, since May 1, 2020, the Company has granted the Awards listed on Schedule 1 attached hereto (the “Award Grants”), with each such grant being approved by the People and Compensation Committee of the Company’s Board of Directors (the “Board”) prior to grant and otherwise purportedly made under the Plan;
WHEREAS, in consultation with counsel, the Board has determined that:
(a)Each of the Award Grants may constitute a “defective corporate act” (as such term is defined in Section 204(h) of the DGCL as a result of the failure of the Award Grants to have been authorized and effected in accordance with the terms of the Plan prior to May 1, 2020;
(b)Each share of Class A Non-Voting Common Stock issued pursuant to the Award Grants (as shown on Schedule 1) (collectively, the “Issuances”) may constitute a share of “putative stock” (as such term is defined in Section 204(h) of the DGCL); and
(c)The amendment of of the Plan, effective as of April 30, 2020, (1) to replace the phrase “the tenth anniversary of the Effective Date” in Section 1.2 with “December 31, 2021” and (2) to increase the number of Authorized Shares specified in Section 3.1 to such number as is sufficient to cover the Award Grants (the “Plan Amendment”) in order to allow for the making of the Award Grants under the Plan may constitute a “defective corporate act” (as such term is defined in Section 204(h) of the DGCL) as a result of the failure of the Plan Amendment to have been authorized and effected in accordance with the terms of the Plan prior to May 1, 2020; and
WHEREAS, the Board has determined that it is advisable and in the best interests of the Company and its stockholders to ratify the Award Grants, the Issuances and the Plan Amendment pursuant to and in accordance with Section 204 of the DGCL.
NOW, THEREFORE, BE IT RESOLVED, that the Award Grants, the Issuances and the Plan
Amendment are the defective corporate acts to be ratified hereby;
RESOLVED, FURTHER, that the date of: (i) each Award Grant is the date of grant set forth on
Schedule 1 with respect to such Award Grant (and Schedule 1 is expressly incorporated herein by
RLF1 26766103v.3
reference); (ii) each Issuance is the date of issuance set forth on Schedule 1 with respect to such
Issuance and (iii) the Plan Amendment was April 30, 2020;
RESOLVED, FURTHER, that the Award Grants and the Issuances have resulted in the issuance of a total of 155,491 shares of Class A Non-Voting Common Stock on the dates, and in the amounts, set forth on Schedule 1 and all such shares of Class A Non-Voting Common Stock constitute shares of putative stock;
RESOLVED, FURTHER, that the nature of the “failure of authorization” (as defined in Section 204(h) of the DGCL) in respect of: (i) each of the Award Grants and each of the Issuances is the failure of the applicable Award Grant to have been authorized and effected in accordance with the terms of the Plan and (ii) the Plan Amendment is the failure of the Plan Amendment to have to have been approved by the Board and voting stockholders of the Company and authorized and effected in accordance with the terms of the Plan;
RESOLVED FURTHER, that pursuant to and in accordance with Section 204 of the DGCL, the ratification of each of the Award Grants, the Issuances and the Plan Amendment be, and hereby is, approved, adopted and confirmed in all respects;
RESOLVED, FURTHER, that the ratification of the Award Grants, the Issuances and the Plan
Amendment be, and hereby is, submitted to holder of the outstanding shares of the Company’s Class B Voting Common Stock, $0.01 par value per share (the “Class B Voting Common Stock”), entitled to vote thereon (the “Voting Stockholder”) for approval and adoption thereby;
RESOLVED, FURTHER, that the Board hereby recommends that the Voting Stockholder approve and adopt the ratification of the Award Grants, the Issuances and the Plan Amendment;
RESOLVED, FURTHER, that the “validation effective time” (as defined in Section 204(h) of the DGCL) in respect of the ratification of the Award Grants, the Issuances and the Plan Amendment shall be the time and date on which the Voting Stockholder approves such ratification;
RESOLVED, FURTHER, that the Plan Amendment be, and hereby is, approved, adopted, ratified and confirmed by the Board in all respects;
RESOLVED, FURTHER, that, subject to the approval of the ratification of the defective corporate acts set forth herein by the Voting Stockholder, each of the Awards granted pursuant to the Award Grants be, and hereby is, ratified on the terms that such Award was originally granted, and each such Award shall be deemed to have been granted under the Plan notwithstanding the provisions of the Plan that may have been in effect without giving effect to the Plan Amendment;
RESOLVED, FURTHER, that, subject to the approval of the ratification of the defective corporate acts set forth herein by the Voting Stockholder, the officers of the Company be, and each of them hereby is, authorized, empowered and directed, for and on behalf of the Company, to deliver a notice of the ratification of the defective corporate acts set forth herein in the form and containing the information required by Sections 204 and 228 of the DGCL;
RESOLVED, FURTHER, that, any time before the relevant validation effective time in respect of the ratification of any of the defective corporate acts identified herein, the Board may abandon the ratification of such act or acts before or after approval thereof by the holder of the outstanding shares of Class B Voting Common Stock without further action by the stockholders of the Company; and RESOLVED, FURTHER, that the officers of the Company be, and each of them hereby is, authorized, empowered and directed, for and on behalf of the Company, to take any and all actions, to negotiate for and enter into agreements and amendments to agreements, to perform all such acts and things, to execute, file, deliver or record in the name and on behalf of the Company, all such certificates,
RLF1 26766103v.3
instruments, agreements or other documents, and to make all such payments as they, in their judgment, or in the judgment of any one or more of them, may deem necessary, advisable or appropriate in order to carry out the purpose and intent of, or consummate the transactions contemplated by the foregoing resolutions and/or all of the transactions contemplated therein or thereby, the authorization therefor to be conclusively evidenced by the taking of such action or the execution and delivery of such certificates, instruments, agreements or documents.
The Secretary of the Company is hereby directed to file a signed copy of this Consent in the minute book of the Company.
IN WITNESS WHEREOF, the undersigned, being all the directors of the Company, have executed this Consent on the date set forth below such stockholder’s name, to be effective as of the date first written above.
| Date: | January 31, 2022 | /s/ MATTHEW W. APPEL | |||||||||
| Matthew W. Appel | |||||||||||
| Date: | January 31, 2022 | /s/ ZENA SRIVATSA ARNOLD | |||||||||
| Zena Srivatsa Arnold | |||||||||||
| Date: | January 31, 2022 | /s/ PHILLIP E. COHEN | |||||||||
| Phillip E. Cohen | |||||||||||
| Date: | January 31, 2022 | /s/ JASON A. KULAS | |||||||||
| Jason A. Kulas | |||||||||||
| Date: | January 31, 2022 | /s/ PABLO LAGOS ESPINOSA | |||||||||
| Pablo Lagos Espinosa | |||||||||||
| Date: | January 31, 2022 | /s/ GARY L. TILLETT | |||||||||
| Gary L Tillett | |||||||||||
RLF1 26766103v.3
| SCHEDULE 1 | ||||||||||||||||||||
| AWARD GRANTS SINCE MAY 1, 2020 | ||||||||||||||||||||
| Name of Recipient | Grant Date | Plan Year | Units Awarded | Vesting Date | Shares Issued | Date of Issuance | ||||||||||||||
| Hugo Dooner | 18-May-20 | Director (2020) | 12,346 | 30-Sep-20 | 12,346 | 2-Oct-20 | ||||||||||||||
| Matt Appel | 22-Dec-20 | Director (2021) | 15,905 | 31-Mar-21 | 15,905 | 1-Apr-21 | ||||||||||||||
| Zena Srivatsa Arnold | 22-Dec-20 | Director (2021) | 15,905 | 31-Mar-21 | 15,905 | 1-Apr-21 | ||||||||||||||
| Shelaghmichael Brown | 22-Dec-20 | Director (2021) | 15,905 | 18-Feb-21 | 15,905 | 6-Mar-21 | ||||||||||||||
| Hugo Dooner | 22-Dec-20 | Director (2021) | 15,905 | 18-Feb-21 | 15,905 | 6-Mar-21 | ||||||||||||||
| Pablo Lagos Espinosa | 22-Dec-20 | Director (2021) | 15,905 | 31-Mar-21 | 15,905 | 1-Apr-21 | ||||||||||||||
| Kent Stone | 22-Dec-20 | Director (2021) | 15,905 | 18-Feb-21 | 15,905 | 6-Mar-21 | ||||||||||||||
| Gary Tillett | 22-Dec-20 | Director (2021) | 15,905 | 31-Mar-21 | 15,905 | 1-Apr-21 | ||||||||||||||
| Robert W.K. Webb | 22-Dec-20 | Director (2021) | 15,905 | 18-Feb-21 | 15,905 | 6-Mar-21 | ||||||||||||||
| Rosa Zeegers | 22-Dec-20 | Director (2021) | 15,905 | 18-Feb-21 | 15,905 | 6-Mar-21 | ||||||||||||||
| Cesar Bertran | 19-Jan-21 | FY20 | 10,964 | 30-Sep-22 | ||||||||||||||||
| Ellen Bryant | 19-Jan-21 | FY20 | 25,599 | 30-Sep-22 | ||||||||||||||||
| Lachie Given | 19-Jan-21 | FY20 | 74,303 | 30-Sep-22 | ||||||||||||||||
| Timothy Jugmans | 19-Jan-21 | FY20 | 17,706 | 30-Sep-22 | ||||||||||||||||
| Jason Kulas | 19-Jan-21 | FY20 | 129,517 | 30-Sep-22 | ||||||||||||||||
| Francisco Kuthy | 19-Jan-21 | FY20 | 61,919 | 30-Sep-22 | ||||||||||||||||
| Caleb Magee | 19-Jan-21 | FY20 | 16,640 | 30-Sep-22 | ||||||||||||||||
| Norma Morales | 19-Jan-21 | FY20 | 10,990 | 30-Sep-22 | ||||||||||||||||
| Miguel Murguia | 19-Jan-21 | FY20 | 9,929 | 30-Sep-22 | ||||||||||||||||
| Blair Powell | 19-Jan-21 | FY20 | 34,674 | 30-Sep-22 | ||||||||||||||||
| Keith Robertson | 19-Jan-21 | FY20 | 41,486 | 30-Sep-22 | ||||||||||||||||
| Sunil Sajnini | 19-Jan-21 | FY20 | 19,249 | 30-Sep-22 | ||||||||||||||||
| Nicole Swies | 19-Jan-21 | FY20 | 19,349 | 30-Sep-22 | ||||||||||||||||
| Juan Pablo Vergara | 19-Jan-21 | FY20 | 10,061 | 30-Sep-22 | ||||||||||||||||
| Damon Vigiolto | 19-Jan-21 | FY20 | 21,284 | 30-Sep-22 | ||||||||||||||||
| Jason Watson | 19-Jan-21 | FY20 | 12,411 | 30-Sep-22 | ||||||||||||||||
| Thomas Welch | 19-Jan-21 | FY20 | 50,773 | 30-Sep-22 | ||||||||||||||||
| Matt Appel | 18-Feb-21 | Director (2022) | 31,936 | 31-Mar-22 | ||||||||||||||||
| Zena Srivatsa Arnold | 18-Feb-21 | Director (2022) | 31,936 | 31-Mar-22 | ||||||||||||||||
| Pablo Lagos Espinosa | 18-Feb-21 | Director (2022) | 31,936 | 31-Mar-22 | ||||||||||||||||
| Gary Tillett | 18-Feb-21 | Director (2022) | 31,936 | 31-Mar-22 | ||||||||||||||||
| Susan Baker | 22-Feb-21 | FY21 | 8,600 | 30-Sep-23 | ||||||||||||||||
| Cesar Bertran | 22-Feb-21 | FY21 | 12,374 | 30-Sep-23 | ||||||||||||||||
| Ellen Bryant | 22-Feb-21 | FY21 | 34,791 | 30-Sep-23 | ||||||||||||||||
| Anne Casey | 22-Feb-21 | FY21 | 3,180 | 30-Sep-23 | ||||||||||||||||
| Nicholas Cohen | 22-Feb-21 | FY21 | 5,964 | 30-Sep-23 | ||||||||||||||||
| Stephen Cox | 22-Feb-21 | FY21 | 3,419 | 30-Sep-23 | ||||||||||||||||
| Michael Croney | 22-Feb-21 | FY21 | 8,548 | 30-Sep-23 | ||||||||||||||||
| Alicia Dombrowski | 22-Feb-21 | FY21 | 2,803 | 30-Sep-23 | ||||||||||||||||
| Lester Durham | 22-Feb-21 | FY21 | 2,985 | 30-Sep-23 | ||||||||||||||||
| Manuel Ferreira | 22-Feb-21 | FY21 | 2,140 | 30-Sep-23 | ||||||||||||||||
| Miguel Garcia | 22-Feb-21 | FY21 | 3,514 | 30-Sep-23 | ||||||||||||||||
| Lachie Given | 22-Feb-21 | FY21 | 119,284 | 30-Sep-23 | ||||||||||||||||
| Issac Gonzalez | 22-Feb-21 | FY21 | 14,351 | 30-Sep-23 | ||||||||||||||||
| Neelima Gullapalli | 22-Feb-21 | FY21 | 10,622 | 30-Sep-23 | ||||||||||||||||
| Brenda Harlicker | 22-Feb-21 | FY21 | 2,994 | 30-Sep-23 | ||||||||||||||||
| Lucy Hernandez | 22-Feb-21 | FY21 | 8,766 | 30-Sep-23 | ||||||||||||||||
| Robert Hicks | 22-Feb-21 | FY21 | 12,425 | 30-Sep-23 | ||||||||||||||||
| Jerry Jory | 22-Feb-21 | FY21 | 15,904 | 30-Sep-23 | ||||||||||||||||
| Timothy Jugmans | 22-Feb-21 | FY21 | 58,846 | 30-Sep-23 | ||||||||||||||||
| Jason Kulas | 22-Feb-21 | FY21 | 253,479 | 30-Sep-23 | ||||||||||||||||
| Francisco Kuthy | 22-Feb-21 | FY21 | 79,522 | 30-Sep-23 | ||||||||||||||||
| Sergio Louro | 22-Feb-21 | FY21 | 8,976 | 30-Sep-23 | ||||||||||||||||
| Adam Matthews | 22-Feb-21 | FY21 | 4,476 | 30-Sep-23 | ||||||||||||||||
| Danelle Miller | 22-Feb-21 | FY21 | 3,194 | 30-Sep-23 | ||||||||||||||||
| Norma Morales | 22-Feb-21 | FY21 | 11,292 | 30-Sep-23 | ||||||||||||||||
| Miguel Murguia | 22-Feb-21 | FY21 | 8,404 | 30-Sep-23 | ||||||||||||||||
| Deborah Myers | 22-Feb-21 | FY21 | 9,194 | 30-Sep-23 | ||||||||||||||||
| Blair Powell | 22-Feb-21 | FY21 | 59,642 | 30-Sep-23 | ||||||||||||||||
| Douglas Reese | 22-Feb-21 | FY21 | 5,816 | 30-Sep-23 | ||||||||||||||||
| Keith Robertson | 22-Feb-21 | FY21 | 53,280 | 30-Sep-23 | ||||||||||||||||
| Sunil Sajnini | 22-Feb-21 | FY21 | 55,666 | 30-Sep-23 | ||||||||||||||||
| Laura Shuford | 22-Feb-21 | FY21 | 10,622 | 30-Sep-23 | ||||||||||||||||
| Brian Smith | 22-Feb-21 | FY21 | 3,677 | 30-Sep-23 | ||||||||||||||||
| Gerhard Stendara | 22-Feb-21 | FY21 | 21,868 | 30-Sep-23 | ||||||||||||||||
| Nicole Swies | 22-Feb-21 | FY21 | 58,846 | 30-Sep-23 | ||||||||||||||||
| Sean Taylor | 22-Feb-21 | FY21 | 5,666 | 30-Sep-23 | ||||||||||||||||
| Mike Teeple | 22-Feb-21 | FY21 | 17,097 | 30-Sep-23 | ||||||||||||||||
| Michael Thompson | 22-Feb-21 | FY21 | 7,952 | 30-Sep-23 | ||||||||||||||||
| Lisa VanRoekel | 22-Feb-21 | FY21 | 55,666 | 30-Sep-23 | ||||||||||||||||
| Juan Pablo Vergara | 22-Feb-21 | FY21 | 8,141 | 30-Sep-23 | ||||||||||||||||
| Damon Vigiolto | 22-Feb-21 | FY21 | 27,335 | 30-Sep-23 | ||||||||||||||||
| Jason Watson | 22-Feb-21 | FY21 | 10,685 | 30-Sep-23 | ||||||||||||||||
| Thomas Welch | 22-Feb-21 | FY21 | 65,208 | 30-Sep-23 | ||||||||||||||||
| Jorge Alvarez | 3-Aug-21 | FY21 | 3,656 | 30-Sep-23 | ||||||||||||||||
| Hemal Sura | 3-Aug-21 | FY21 | 1,066 | 30-Sep-23 | ||||||||||||||||
| Blair Powell | 13-Oct-21 | Special | 29,722 | 30-Sep-22 | ||||||||||||||||
| Lachie Given | 13-Oct-21 | FY22 | 79,260 | 30-Sep-24 | ||||||||||||||||
| Timothy Jugmans | 13-Oct-21 | FY22 | 55,482 | 30-Sep-24 | ||||||||||||||||
| Jason Kulas | 13-Oct-21 | FY22 | 280,713 | 30-Sep-24 | ||||||||||||||||
| Francisco Kuthy | 13-Oct-21 | FY22 | 39,630 | 30-Sep-24 | ||||||||||||||||
| Blair Powell | 13-Oct-21 | FY22 | 59,445 | 30-Sep-24 | ||||||||||||||||
| Keith Robertson | 13-Oct-21 | FY22 | 35,402 | 30-Sep-24 | ||||||||||||||||
| Sunil Sajnini | 13-Oct-21 | FY22 | 36,988 | 30-Sep-24 | ||||||||||||||||
| Nicole Swies | 13-Oct-21 | FY22 | 44,940 | 30-Sep-24 | ||||||||||||||||
| Lisa VanRoekel | 13-Oct-21 | FY22 | 36,988 | 30-Sep-24 | ||||||||||||||||
| Thomas Welch | 13-Oct-21 | FY22 | 43,328 | 30-Sep-24 | ||||||||||||||||
| Jorge Alvarez | 16-Nov-21 | FY22 | 6,525 | 30-Sep-24 | ||||||||||||||||
| Susan Baker | 16-Nov-21 | FY22 | 5,719 | 30-Sep-24 | ||||||||||||||||
| Cesar Bertran | 16-Nov-21 | FY22 | 8,454 | 30-Sep-24 | ||||||||||||||||
| Ellen Bryant | 16-Nov-21 | FY22 | 24,438 | 30-Sep-24 | ||||||||||||||||
| Anne Casey | 16-Nov-21 | FY22 | 2,179 | 30-Sep-24 | ||||||||||||||||
| Nicholas Cohen | 16-Nov-21 | FY22 | 5,442 | 30-Sep-24 | ||||||||||||||||
| Stephen Cox | 16-Nov-21 | FY22 | 6,605 | 30-Sep-24 | ||||||||||||||||
| Michael Croney | 16-Nov-21 | FY22 | 7,133 | 30-Sep-24 | ||||||||||||||||
| Alicia Dombrowski | 16-Nov-21 | FY22 | 1,928 | 30-Sep-24 | ||||||||||||||||
| Lester Durham | 16-Nov-21 | FY22 | 3,302 | 30-Sep-24 | ||||||||||||||||
| Manuel Ferreira | 16-Nov-21 | FY22 | 1,836 | 30-Sep-24 | ||||||||||||||||
| Miguel Garcia | 16-Nov-21 | FY22 | 2,417 | 30-Sep-24 | ||||||||||||||||
| Arturo Gonzalez | 16-Nov-21 | FY22 | 3,857 | 30-Sep-24 | ||||||||||||||||
| Issac Gonzalez | 16-Nov-21 | FY22 | 9,643 | 30-Sep-24 | ||||||||||||||||
| Neelima Gullapalli | 16-Nov-21 | FY22 | 7,318 | 30-Sep-24 | ||||||||||||||||
| Belinda Harlicker | 16-Nov-21 | FY22 | 2,060 | 30-Sep-24 | ||||||||||||||||
| Lucy Hernandez | 16-Nov-21 | FY22 | 6,420 | 30-Sep-24 | ||||||||||||||||
| Robert Hicks | 16-Nov-21 | FY22 | 9,907 | 30-Sep-24 | ||||||||||||||||
| Jerry Jory | 16-Nov-21 | FY22 | 10,885 | 30-Sep-24 | ||||||||||||||||
| Michael Keim | 16-Nov-21 | FY22 | 1,770 | 30-Sep-24 | ||||||||||||||||
| Sharon Knitter | 16-Nov-21 | FY22 | 13,870 | 30-Sep-24 | ||||||||||||||||
| Sergio Louro | 16-Nov-21 | FY22 | 9,247 | 30-Sep-24 | ||||||||||||||||
| Adam Matthews | 16-Nov-21 | FY22 | 3,302 | 30-Sep-24 | ||||||||||||||||
| Danelle Miller | 16-Nov-21 | FY22 | 5,614 | 30-Sep-24 | ||||||||||||||||
| Norma Morales | 16-Nov-21 | FY22 | 7,291 | 30-Sep-24 | ||||||||||||||||
| Miguel Murguia | 16-Nov-21 | FY22 | 5,746 | 30-Sep-24 | ||||||||||||||||
| Deborah Myers | 16-Nov-21 | FY22 | 7,529 | 30-Sep-24 | ||||||||||||||||
| Douglas Reese | 16-Nov-21 | FY22 | 6,605 | 30-Sep-24 | ||||||||||||||||
| Laura Shuford | 16-Nov-21 | FY22 | 7,278 | 30-Sep-24 | ||||||||||||||||
| Brian Smith | 16-Nov-21 | FY22 | 2,443 | 30-Sep-24 | ||||||||||||||||
| Gerhard Stendara | 16-Nov-21 | FY22 | 14,531 | 30-Sep-24 | ||||||||||||||||
| Hemal Sura | 16-Nov-21 | FY22 | 2,972 | 30-Sep-24 | ||||||||||||||||
| Sean Taylor | 16-Nov-21 | FY22 | 3,764 | 30-Sep-24 | ||||||||||||||||
| Mike Teeple | 16-Nov-21 | FY22 | 11,704 | 30-Sep-24 | ||||||||||||||||
| Michael Thompson | 16-Nov-21 | FY22 | 5,442 | 30-Sep-24 | ||||||||||||||||
| Luis David Valdez | 16-Nov-21 | FY22 | 700 | 30-Sep-24 | ||||||||||||||||
| Juan Pablo Vergara | 16-Nov-21 | FY22 | 5,799 | 30-Sep-24 | ||||||||||||||||
| Damon Vigiolto | 16-Nov-21 | FY22 | 19,550 | 30-Sep-24 | ||||||||||||||||
| Jason Watson | 16-Nov-21 | FY22 | 7,926 | 30-Sep-24 | ||||||||||||||||
| Totals | 3,043,074 | 155,491 | ||||||||||||||||||
| Forfeited after grant | (680,349) | |||||||||||||||||||
| 2,362,725 | ||||||||||||||||||||